Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy

Cancer Biology and Therapy

Volumn 14, Issue 8, 2013, Pages 761-772

  Heffler, Melissa ^a   Golubovskaya, Vita M ^a   Dunn, Kelli M Bullard ^b   Cance, William ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Colon carcinoma; Focal adhesion kinase; Small molecule inhibitors; SW480 cells; SW620

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; FLUOROURACIL; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; OXALIPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL VIABILITY; CLONOGENESIS; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE SRC; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; WESTERN BLOTTING;

COLON CARCINOMA; FOCAL ADHESION KINASE; SMALL MOLECULE INHIBITORS; SW480 CELLS; SW620;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHENYLENEDIAMINES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881431783     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25185     Document Type: Article

References (26)

1. American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. In: Society AC, ed. Atlanta, 2011.
2. Golubovskaya VM, Kweh FA, Cance WG. Focal adhesion kinase and cancer. Histol Histopathol 2009; 24:503-10; PMID:19224453
3. Figel S, Gelman IH. Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. Anticancer Agents Med Chem 2011; 11:607-16; PMID:21355844; http://dx.doi. org/10.2174/ 187152011796817646
4. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000; 6:2417-23; PMID:10873094
5. Golubovskaya VM, Cance WG. Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 2007; 263:103-53; PMID:17725966; http://dx.doi. org/10.1016/S0074-7696(07)63003-4
6. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51:7405-16; PMID:18989950; http://dx.doi.org/10.1021/jm800483v
7. Bolós V, Gasent JM, López-Tarruella S, Grande E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther 2010; 3:83-97; PMID:20616959; http://dx.doi.org/10.2147/OTT.S6909
8. Golubovskaya VM, Gross S, Kaur AS, Wilson RI, Xu LH, Yang XH, et al. Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol Cancer Res 2003; 1:755-64; PMID:12939401
9. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51:7405-16; PMID:18989950; http://dx.doi.org/10.1021/jm800483v
10. Xu LH, Yang X, Bradham CA, Brenner DA, Baldwin AS, Craven RJ, et al. The focal adhesion kinase suppresses transformation-associated anchorageindependent apoptosis in human breast cancer cells. J Biol Chem 2000; 275:30597-604; http://dx.doi. org/10.1074/jbc.M910027199
11. Golubovskaya VM, Zheng M, Zhang L, Li JL, Cance WG. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 2009; 9:280-8; PMID:19671193; http://dx.doi.org/10.1186/1471-2407-9-280
12. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-proteincoupled receptors with MAP kinase activation. Nature 1996; 383:547-50; PMID:8849729; http://dx.doi. org/10.1038/383547a0
13. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008; 68:1935-44; PMID:18339875; http://dx.doi.org/10.1158/0008-5472.CAN-07-5155
14. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67:10976-83; PMID:18006843; http://dx.doi.org/10.1158/0008-5472.CAN-07-2667
15. Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, et al. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol Rep 2008; 20:1473-7; PMID:19020730
16. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther 2010; 9:764-77; PMID:20234191; http://dx.doi.org/10.4161/cbt.9.10.11434
17. Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, et al. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 2010; 9:1005-15; PMID:20160475; http://dx.doi.org/10. 4161/cc.9.5.10936
18. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009; 8:2435-43; PMID:19571674; http://dx.doi.org/10.4161/cc. 8.15.9145
19. Topley P, Jenkins DC, Jessup EA, Stables JN. Effect of reconstituted basement membrane components on the growth of a panel of human tumour cell lines in nude mice. Br J Cancer 1993; 67:953-8; PMID:8494729; http://dx.doi.org/10. 1038/bjc.1993.176
20. Trainer DL, Kline T, McCabe FL, Faucette LF, Feild J, Chaikin M, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 1988; 41:287-96; PMID:3338874; http://dx.doi.org/10.1002/ijc.2910410221
21. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008; 14:627-32; PMID:18245520; http://dx.doi. org/10.1158/1078-0432.CCR- 07-2220
22. Beierle EA, Ma X, Trujillo A, Kurenova EV, Cance WG, Golubovskaya VM. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol Carcinog 2010; 49:224-34; PMID:19885861
23. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999; 71:435-78; PMID:10354709; http://dx.doi. org/10.1016/S0079-6107(98)00052-2
24. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-41; PMID:16775234; http://dx.doi.org/10.1056/ NEJMoa055229
25. Heffler M, Golubovskaya VM, Cance WG, Bullard Dunn KM. Evolving molecular therapeutics and their applications to surgical oncology. American College of Surgeons: Principles and Practice. Chicago (IL): American College of Surgeons, 2011.
26. Lai E, Singh R, Teng B, Zhao Y, Sharratt E, Howell G, et al. Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth in mice. Dis Colon Rectum 2010; 53:475-82; PMID:20305449; http://dx.doi.org/10.1007/DCR. 0b013e3181c87084